Access Bio

At a glance

Access Bio filed 26 disclosures in the last 12 months, including 2 insider, 1 contract and 1 5% holder. The most recent key filing was on Oct 20: Worth 15.9% of last year's revenue, over about 12 months.

Revenue for 2025 was ₩22M, down 73.3% on 2024. It made an operating loss of ₩44.5M. Debt was 9% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩10.1M and operating loss of ₩23.6M.

The 2025 annual report lists 75 employees with an average tenure of 4.7 years and average pay of ₩159M, #22 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩292M each on average. It paid no cash dividend for 2025. (주)팜젠사이언스 and related parties held 24.72% at year end.

From the 2025 annual report

Staff: 75 (50 men, 25 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩11.9B. Directors and auditors: 9, paid ₩2.6B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)팜젠사이언스 holds 24.31%; with 4 related parties the group holds 24.72% of common shares at year end (from 24.31% at the start of the year).

Individuals paid ₩500M or more

Auditor: 우리회계법인 · opinion: Unqualified.

Rankings: Average pay #22 of 1,829

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 16% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary